A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
研究单位：[1]Hoffmann-La Roche[2]Medizinische Universität Innsbruck[3]Universitätsklinik für Innere Medizin I,Innsbruck,Austria,6020[4]Uniklinikum Salzburg, LKH[5]Univ.Klinik f. Innere Medizin III der PMU,Salzburg,Austria,5020[6]Universitätsklinikum St. Pölten[7]Innere Medizin 2,St. Pölten,Austria,3100[8]Klinik Favoriten[9]Abteilung für Chirurgie,Wien,Austria,1100[10]Imeldaziekenhuis,Bonheiden,Belgium,2820[11]AZ KLINA,Brasschaat,Belgium,2930[12]Hospital Erasme,Bruxelles,Belgium,1070[13]Cliniques Universitaires St-Luc,Bruxelles,Belgium,1200[14]UZ Gent,Gent,Belgium,9000[15]UZ Leuven,Leuven,Belgium,3000[16]AZ Delta (Campus Rumbeke),Roeselare,Belgium,8800[17]Hospital Sao Rafael - HSR,Salvador,BA,Brazil,41253-190[18]Sociedade beneficente de senhoras Hospital Sirio Libanes,Brasilia,DF,Brazil,70200-730[19]Hospital Felicio Rocho,Belo Horizonte,MG,Brazil,30110-068[20]Clinicas Oncologicas Integradas - COI,Rio De Janeiro,RJ,Brazil,22290-160[21]Hospital Moinhos de Vento,Porto Alegre,RS,Brazil,90035-000[22]Hospital Sao Lucas - PUCRS,Porto Alegre,RS,Brazil,90610-000[23]YNOVA Pesquisa Clinica,Florianopolis,SC,Brazil,88020-210[24]Centro Paulista de Oncologia,Sao Paulo,SP,Brazil,04538-132[25]Beneficencia Portuguesa de Sao Paulo,São Paulo,SP,Brazil,01321-00[26]Multiprofile Hospital for Active Treatment Uni Hospital[27]Department of medicinal oncology,Panagyurishte,Bulgaria,4500[28]Complex Oncological Center - Plovdiv, EOOD[29]Second Internal Department,Plovdiv,Bulgaria,4004[30]MHAT Sveta Sofia[31]Department of medical oncology,Sofia,Bulgaria,1618[32]MHAT SofiaMed[33]OOD,Sofia,Bulgaria[34]SHATOD Dr. Marko Antonov Markov-Varna, EOOD[35]Department of Medicinall Onchotherapy and Palliative,Varna,Bulgaria,9010[36]Tom Baker Cancer Centre-Calgary,Calgary,Alberta,Canada,T2N 4N2[37]Cross Cancer Institute,Edmonton,Alberta,Canada,T6G 1Z2[38]Juravinski Cancer Centre,Hamilton,Ontario,Canada,L8V 5C2[39]Princess Margaret Cancer Center,Toronto,Ontario,Canada,M5G 2M9[40]Centro de Estudios Clínicos SAGA,Santiago,Chile,7500653[41]Hospital Clinico de La Universidad de Chile J.J.A.[42]Oncologia,Santiago,Chile,8380456[43]Pontificia Universidad Catolica de Chile[44]Clinica San Carlos de Apoquindo,Santiago,Chile[45]The Fifth Medical Center of People''s Liberation Army General Hospital,Beijing City,China,100039[46]Peking University People''s Hospital,Beijing,China,100044[47]Hunan Cancer Hospital,Changsha CITY,China,410013[48]West China Hospital - Sichuan University,Chengdu City,China,610047[49]Sichuan Provincial Cancer Hospital,Chengdu,China,610041[50]Fujian Provincial Hospital,Fuzhou City,China,350001[51]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou City,China,510080[52]Sun Yet-sen University Cancer Center,Guangzhou City,China,510663[53]Nanfang Hospital, Southern Medical University,Guangzhou,China,510515[54]Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University,Hangzhou,China,310016[55]Harbin Medical University Cancer Hospital,Harbin,China,150081[56]Anhui Province Cancer Hospital,Hefei City,China,230031[57]Shandong Provincial Hospital,Jinan,China,250021[58]Shandong Cancer Hospital,Jinan,China,250117[59]Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University),Nanjing City,China,210029[60]Zhongshan Hospital Fudan University,Shanghai,China,200032[61]Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China,200127[62]Shengjing Hospital of China Medical University,ShenYang,China,110004[63]Tianjin Cancer Hospital,Tianjin,China,300060[64]Tongji Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan City,China,430030
研究目的：
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.
